Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
What dose would you give for LRC for a PEcoma (perivascular epitheliod cell tumor) of the anal canal?
Related Questions
What's your follow-up protocol for a near complete response (nCR) in rectal patients considering non-operative management (NOM)?
Would having mucinous rectal adenocarcinoma impact your recommendation for short vs long course RT as part of a TNT regimen?
How would you manage a patient with de novo oligometastatic anal cancer with a single metastasis in the pubic bone?
What are your top takeaways in GI Cancers from ESMO 2025?
What dose and fractionation do you utilize for node positive HCC?
Is there increased risk from RT in patients with FAP (familial adenomatous polyposis)?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
Are the results of CONKO-007 changing practice for the management of pancreatic cancer?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
What treatment sequence do you follow for patients with rectal cancer who are candidates for both PROSPECT and TNT/Watch and wait?
